Metabolic effects of bezafibrate in mitochondrial disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Mitochondrial disorders affect 1/5,000 and have no cure. Inducing mitochondrial biogenesis with bezafibrate improves mitochondrial function in animal models, but there are no comparable human studies. We performed an open-label observational experimental medicine study of six patients with mitochondrial myopathy caused by the m.3243A>G MTTL1 mutation. Our primary aim was to determine the effects of bezafibrate on mitochondrial metabolism, whilst providing preliminary evidence of safety and efficacy using biomarkers. The participants received 600-1,200 mg bezafibrate daily for 12 weeks. There were no clinically significant adverse events, and liver function was not affected. We detected a reduction in the number of complex IV-immunodeficient muscle fibres and improved cardiac function. However, this was accompanied by an increase in serum biomarkers of mitochondrial disease, including fibroblast growth factor 21 (FGF-21), growth and differentiation factor 15 (GDF-15), plus dysregulation of fatty acid and amino acid metabolism. Thus, although potentially beneficial in short term, inducing mitochondrial biogenesis with bezafibrate altered the metabolomic signature of mitochondrial disease, raising concerns about long-term sequelae.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Salmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
An atlas of genetic influences on human blood metabolites
The Multiple Tissue Human Expression Resource (MuTHER) Consortium, Shin, S.-Y., Fauman, E. B., Petersen, A.-K., Krumsiek, J., Santos, R., Huang, J., Arnold, M., Erte, I., Forgetta, V., et al. (2014) · Nature Genetics · doi:10.1038/ng.2982 · Cited by 1,515
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins
Calvo, S. E., Clauser, K. R., & Mootha, V. K. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1003 · Cited by 1,251
A novel, open access method to assess sleep duration using a wrist-worn accelerometer
van Hees, V. T., Sabia, S., Anderson, K. N., Denton, S. J., Oliver, J., Catt, M., Abell, J. G., Kivimäki, M., Trenell, M. I., & Singh-Manoux, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142533 · Cited by 744
NAD+-Dependent Activation of Sirt1 Corrects the Phenotype in a Mouse Model of Mitochondrial Disease
Cerutti, R., Pirinen, E., Lamperti, C., Marchet, S., Sauve, A. A., Li, W., Leoni, V., Schon, E. A., Dantzer, F., Auwerx, J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.001 · Cited by 343 · cited 2×
“…show promise in pre-clinical studies, including agonists of AMPprotein activated kinase (Viscomi et al, 2011; Peralta et al, 2016), peroxisome proliferator-activated receptor (PPAR) (Yatsuga & Suomalainen, 2012; Benit et al, 2017), sirtuins (Cerutti et al, 2014) and Nrf2 (Hayashi et al, 2017).”
BackgroundSelf-citationMullen, A. R., Hu, Z., Shi, X., Jiang, L., Boroughs, L. K., Kovacs, Z., Boriack, R., Rakheja, D., Sullivan, L. B., Linehan, W. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.037 · Cited by 337 · cited 1×
“Glutamine is an abundant circulating amino acid and has an anaplerotic role, replenishing TCA cycle intermediates, which drive the mitochondrial respiratory chain to generate reducing equivalents (Mullen et al, 2014; Chen et al, 2018).”
BackgroundPyle, A., Hudson, G., Wilson, I. J., Coxhead, J., Smertenko, T., Herbert, M., Santibanez-Koref, M., & Chinnery, P. F. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005040 · Cited by 77 · cited 1×
“Measurement of m.3243A>G heteroplasmy (de Laat et al, 2016) and mtDNA levels (Pyle et al, 2015) were quantified following previously reported methods.”
MethodSelf-citation
Cited by
Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease
Misrani, A., Tabassum, S., & Yang, L. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.617588 · Cited by 654
Mitochondrial DNA copy number in human disease: the more the better?
Filograna, R., Mennuni, M., Alsina, D., & Larsson, N. (2021) · FEBS Letters · doi:10.1002/1873-3468.14021 · Cited by 478
Jurcău, M. C., Andronie-Cioara, F. L., Jurcău, A., Marcu, F., Ţiț, D. M., Pașcalău, N., & Nistor-Cseppentö, D. C. (2022) · Antioxidants · doi:10.3390/antiox11112167 · Cited by 226
“Bezafibrate, a drug currently used to treat dyslipidemia, is also a PPAR agonist shown to improve mitochondrial biogenesis [197], which makes it a promising therapeutic agent in many neurodegenerative diseases, but which has not been tested yet in clinical setting.”
BackgroundModelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?
McKnight, C. L., Low, Y. C., Elliott, D. A., Thorburn, D. R., & Frazier, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147730 · Cited by 27
Metadata
- Authors
- Steele, H., Gomez‐Duran, A., Pyle, A., Hopton, S., Newman, J., Stefanetti, R. J., Charman, S. J., Parikh, J. D., He, L., Viscomi, C., Jakovljevic, D. G., Hollingsworth, K. G., Robinson, A. J., Taylor, R. W., Bottolo, L., Horvath, R., & Chinnery, P. F.
- Venue
- EMBO Molecular Medicine
- Published
- 2020-02-28
- Volume
- 12
- Issue
- 3
- Pages
- e11589-e11589
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3008617433
- Cited by
- 82
- References
- 9
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic effects of bezafibrate in mitochondrial disease. https://app.cochat.ai/papers/10.15252/emmm.201911589
- The paper
- Steele, H., Gomez‐Duran, A., Pyle, A., Hopton, S., Newman, J., Stefanetti, R. J., Charman, S. J., Parikh, J. D., He, L., Viscomi, C., Jakovljevic, D. G., Hollingsworth, K. G., Robinson, A. J., Taylor, R. W., Bottolo, L., Horvath, R., & Chinnery, P. F. (2020). Metabolic effects of bezafibrate in mitochondrial disease. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201911589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.